Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 20 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

20 recruiting

Enrollment Performance

Analytics

Phase 1
20(100.0%)
20Total
Phase 1(20)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT07598955Phase 1Recruiting

Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma

Role: lead

NCT07589517Phase 1Recruiting

Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

Role: lead

NCT07589543Phase 1Recruiting

Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

Role: lead

NCT07589530Phase 1Recruiting

Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

Role: lead

NCT07551362Phase 1Recruiting

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

Role: lead

NCT07551349Phase 1Recruiting

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Role: lead

NCT07551336Phase 1Recruiting

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Role: lead

NCT07523542Phase 1Recruiting

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Role: lead

NCT07523555Phase 1Recruiting

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Role: lead

NCT07523529Phase 1Recruiting

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Role: lead

NCT07502287Phase 1Recruiting

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Role: lead

NCT07500220Phase 1Recruiting

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Role: lead

NCT07492628Phase 1Recruiting

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Role: lead

NCT07486089Phase 1Recruiting

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Role: lead

NCT07480954Phase 1Recruiting

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

Role: lead

NCT07480213Phase 1Recruiting

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Role: lead

NCT07480941Phase 1Recruiting

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Role: lead

NCT07480928Phase 1Recruiting

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Role: lead

NCT07467863Phase 1Recruiting

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

Role: lead

NCT07462650Phase 1Recruiting

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

Role: lead

All 20 trials loaded